Table 2.
BMI > 30 (n = 171) | BMI ≤ 30 (n = 121) | P-value | |
---|---|---|---|
Treatment of COVID-19 | |||
- Low dose corticosteroids (up to 8 mg dexamethasone/day) | 71.3% (122) | 81.8% (99) | 0.04 |
- High dose corticosteroids (>8 mg dexamethasone or >40 mg methylprednisolone/day) | 28.1% (48) | 6.6% (8) | <0.001 |
- Isoprinosine | 70.8% (121) | 67.8% (82) | 0.584 |
- Remdesivir | 41.5% (71) | 61.2% (74) | <0.001 |
- Monoclonal antibodies⁎ | 9.4% (16) | 19% (23) | 0.018 |
- Baricitinib | 2.9% (5) | 5% (6) | 0.368 |
- Tocilizumab | 1.2% (2) | 1.7% (2) | 0.726 |
NIV/HFNO (days) | 2 (1–4) | 2 (0–5) | 0.702 |
Tracheostomy | 75.4% (129) | 69.4% (84) | 0.254 |
Intubation to tracheostomy interval (days) | 8 (5–9) | 7 (6–9) | 0.552 |
Initiation of PSV post intubation (days) | 5.5 (3–9) | 5 (2–7) | 0.023 |
Prone position | 62% (106) | 59.5% (72) | 0.623 |
VV ECMO | 45% (77) | 34.7% (42) | 0.087 |
|
29 (25–29) | 27 (25–29) | 0.503 |
|
23 (21−23) | 23 (21–23) | 0.726 |
|
4.7 (4.2–5.2) | 4.6 (4.2–5) | 0.631 |
|
3 (2.5–4) | 3 (2.5–3.5) | 0.459 |
ECMO retrieval | 34.5% (59) | 23.1% (28) | 0.85 |
|
5 (2–9) | 7 (4–10) | 0.021 |
ECMO duration (days) | 14 (8–24) | 14 (9–23) | 0.775 |
|
62.3% (48) | 59.5% (25) | 0.845 |
circuit thrombosis | 3.5% (6) | 0 | 0.519 |
number of circuits used | 2 (1–3) | 2 (1–2) | 0.570 |
duration of MV or NIV prior to ECMO initiation (days) | 3 (1–5) | 2 (1–4) | 0.201 |
prone on ECMO | 30.7% (23) | 28.6% (12) | 0.837 |
|
6 (5–13) | 7 (3−10) | 0.447 |
Table 2: Comparison of therapy in the obese versus non-obese groups (numbers and percentages or medians with interquartile ranges, compared with Mann-Whitney U or the Fischer's exact tests).
Monoclonal antibodies available since 2021; NIV, noninvasive ventilation; HFNO, high flow nasal oxygen; PSV, pressure support ventilation; MV, mechanical ventilation; circuit thrombosis = pump head thrombosis requiring urgent resetting. Interval from ICU admission to ECMO starts at the referring hospital ICU admission. Initial fraction of oxygen on the ECMO blender (FsO2) was 100% in all patients.